Back to Journals » OncoTargets and Therapy » Volume 14

Apatinib Combined with Irinotecan in the Treatment of Advanced Small-Cell Esophageal Carcinoma: A Case Report

Authors Guo L, Zou X, Gu Y, Yi L, Zhao J, Wu G

Received 1 December 2020

Accepted for publication 16 February 2021

Published 18 March 2021 Volume 2021:14 Pages 1989—1995

DOI https://doi.org/10.2147/OTT.S295067

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Geoffrey Pietersz


Longhua Guo,1 Xiaofang Zou,1 Yinfang Gu,1 Lilan Yi,1 Jingjing Zhao,2 Guowu Wu1

1Department of Medical Oncology, Cancer Center, Meizhou People’s Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-Sen University, Meizhou, 514031, People’s Republic of China; 2Department of Biotherapy, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People’s Republic of China

Correspondence: Jingjing Zhao
State Key Laboratory of Oncology in South China; Department of Biotherapy, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People’s Republic of China
Tel +86-20-87345699
Fax +86-20-87343392
Email [email protected]
Correspondence: Guowu Wu
Department of Medical Oncology, Cancer Center, Meizhou People’s Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-Sen University, 63 Huangtang Road, Meizhou, 514031, People’s Republic of China
Tel +86-753-2131682
Fax +86-753-2204840
Email [email protected]

Abstract: Chemotherapy is the mainstay of treatment for advanced small cell esophageal carcinoma (SCEC) characterized by poor prognosis. Preclinical studies demonstrated that apatinib has the potential to enhance the efficacy of conventional chemotherapeutic drugs and reverse multidrug resistance (MDR). This report described the application of apatinib combined with irinotecan as the third-line treatment for advanced SCEC in a 54-year-old male patient. His symptoms of upper abdominal pain and distension were ameliorated notably after the combination therapy. Computed tomography (CT) examination revealed the treatment efficacy was partial response (PR). The progression-free survival (PFS) and overall survival (OS) were 12.5 months and 28 months, respectively. The treatment-related toxicity was manageable. Apatinib combined with chemotherapy may serve as a new treatment choice for advanced SCEC patients. However, further studies should be conducted to confirm the therapeutic value of this combination regimen in advanced SCEC.

Keywords: small cell esophageal carcinoma, apatinib, irinotecan, progression-free survival, overall survival

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]